

Cellnovo update on progress towards full-scale manufacturing of insulin cartridges by Flex

Production capacity of insulin cartridges at Cellnovo's South Wales manufacturing facility to increase significantly

Full commercial production of insulin cartridges from Flex expected early in Q2 2017

Paris, France, December 15, 2016 - Cellnovo Group ("Cellnovo" CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today provides an update on progress towards the buildup to full-scale manufacturing of its mobile, connected, all-in-one diabetes management system by Flex.

Following the delivery of the first pilot batch of insulin cartridges announced in September, Cellnovo and Flex have achieved two additional milestones.

First, a ramp up of the wax actuator assembly production at the Flex facility that will result in a 50% capacity increase at Cellnovo's South Wales manufacturing facility in Q1 2017.

Secondly, further improvements have been made to the Flex manufacturing processes to increase the yield and quality of the full insulin cartridge.

Full commercial production of the insulin cartridges is expected for early Q2 2017. The capacity of the Flex production line in Austria (Althofen) will be fully scalable, with potential to meet customer demand, in line with 2017 expectations.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: *"Progress towards full completion of the manufacturing transfer to Flex continues steadily while taking more time than previously expected. Delivery of the wax actuator assemblies significantly increases the near-term production capacity at our facility in South Wales. Given the high levels of demand for our product, this increase will help meet patients' short term needs ahead of a more significant capacity increase on achieving full manufacturing transfer in early Q2 2017."*

...

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.

For further information please visit www.cellnovo.com



The First Connected All-in-one Diabetes Management System

About the Cellnovo Diabetes Management System

Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Tristan Roquet Montégon
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Chris Gardner, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

